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Objective: The potential association of mannose binding lectin (MBL) deﬁciency and systemic
lupus erythematosus (SLE) has been investigated in several studies, but results have been
mixed. One explanation for the conﬂicting results could be differences in ethnic background
of  study subjects. In this study we investigated the association of MBL deﬁciency and SLE in
a  large cohort of Brazilian SLE patients and controls.
Methods: Serum MBL and Complement levels were determined for 286 Brazilian adult SLE
patients and 301 healthy Brazilian adults as controls. MBL deﬁciency was classiﬁed as mild
(<1000 and ≥500 g/L), moderate (<500 and ≥100 g/L) or severe (<100 g/L).
Results: SLE patients presented higher frequency of mild and moderate MBL deﬁciency com-
pared  to controls. SLE patients with MBL deﬁciency presented higher frequency of lupus
nephritis compared to those without MBL deﬁciency. MBL deﬁciency was not associated
with  any other clinical manifestation, use of immunosuppressant therapy, disease activity,
disease severity serum or Complement levels.
Conclusion: This study shows that an association between MBL deﬁciency and SLE does exist
in  the Brazilian population. We  also found an association between MBL deﬁciency and lupus
nephritis. These ﬁndings support the hypothesis that MBL deﬁciency contributes to thedevelopment of SLE and lupus nephritis.
© 2015 Elsevier Editora Ltda. All rights reserved. Manuscript winner of the “Young scientist prize of the year from the Brazilian Society of Rheumatology-Clinical area” for
Sandro  F. Perazzio in XXXI Brazilian Congress of Rheumatology, Belo Horizonte, MG, Brazil, 2014.
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As  deﬁciências  leve  e  moderada  de  lectina  ligadora  de  manose  estão
associadas  ao  lúpus  eritematoso  sistêmico  e  à  nefrite  lúpica  em  pacientes
brasileiros
Palavras-chave:
Deﬁciência de LLM
Lúpus eritematoso sistêmico
Imunodeﬁciência
Nefrite lúpica
r  e  s  u  m  o
Objetivo: Vários estudos já investigaram a potencial associac¸ão entre a deﬁciência de lectina
de  ligac¸ão a manose (LLM) e o lúpus eritematoso sistêmico (LES), mas os resultados obtidos
são  mistos. Uma explicac¸ão para esses resultados conﬂitantes poderia estar nas diferenc¸as
étnicas dos indivíduos estudados. Este estudo investigou a associac¸ão entre a deﬁciência de
LLM  e o LES em uma grande coorte de pacientes brasileiros com LES e controles.
Métodos: Determinaram-se os níveis séricos de LLM e complemento em 286 pacientes
adultos brasileiros com LES e 301 adultos brasileiros saudáveis que atuaram como con-
troles. A deﬁciência de LLM foi classiﬁcada como leve (<1000 e ≥ 500 g/L), moderada
(<500 e ≥ 100 g/L) ou grave (<100 g/L).
Resultados: Os pacientes com LES apresentaram uma maior frequência de deﬁciência leve e
moderada de LLM em relac¸ão aos controles. Os pacientes com LES com deﬁciência de LLM
apresentaram uma maior frequência de nefrite lúpica em comparac¸ão com aqueles sem
deﬁciência de LLM. A deﬁciência de LLM não esteve associada a qualquer outra manifestac¸ão
clínica, uso de terapia imunossupressora, atividade da doenc¸a, gravidade da doenc¸a ou
níveis séricos de complemento.
Conclusão: Este estudo mostra que há uma associac¸ão entre a deﬁciência de LLM e o LES
na  populac¸ão brasileira. Encontrou-se também uma associac¸ão entre a deﬁciência de LLM
e  a nefrite lúpica. Esses resultados apoiam a hipótese de que a deﬁciência de LLM contribui
para  o desenvolvimento do LES e da nefrite lúpica.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
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dence of autoimmune disease according to a structuredntroduction
annose binding lectin (MBL), an important component of
he innate immune defense system, has the capacity to bind
icroorganism surface polysaccharides and subsequently
ctivate the Complement system through the MASP (MBL
ssociated serine proteases) family of proteases. MBL  is func-
ionally similar and structurally homologous to C1q, the ﬁrst
omponent of the classical Complement pathway.1
The MBL  gene contains 4 exons and its chromosome loca-
ion is 10q11.2–q21. Five single nucleotide polymorphisms
SNPs) have been reported to be associated with reduced MBL
erum protein levels. The most common SNPs are located on
xon 1, at codons 52 (+223), 54 (+230), and 57 (+239), respec-
ively designated alleles D, B and C (the “wild” type allele is
esignated A).2 In addition, polymorphisms of the MBL pro-
oter region are also reported to inﬂuence serum protein
evels.3 The frequency of the abnormal alleles differs signif-
cantly according to ethnic background.4
MBL  polymorphism has been reported in association with
everal autoimmune diseases, including type I diabetes5 and
heumatoid arthritis.6 Several studies suggest an association
etween MBL  deﬁciency or gene polymorphism and sys-
emic lupus erythematosus (SLE).7 It has been postulated
hat MBL  deﬁciency might result in inefﬁcient clearance of
poptotic cells and predisposition to infections. This, in turn,
ay lead to over-expression of autoantigens that could con-ribute to autoantibody generation and SLE development.7
 meta-analysis of 8 studies published in 2001 showed that
he presence of abnormal alleles confers a 1.6 fold increase inrisk for developing SLE.8 Four years later, Lee et al.9 demon-
strated that a SNP at MBL codon 54 (designated allele B) and
polymorphisms in the MBL promoter region were risk factors
of SLE development. However, several other studies failed to
demonstrate an association between SLE and MBL  deﬁciency.
This discrepancy may be related to the heterogeneous eth-
nic backgrounds of subjects in those studies.10,11 It is possible
that other genetic factors, perhaps related to ethnic back-
ground, are required for the development of SLE in individuals
with MBL  deﬁciency or gene polymorphism.2 Therefore, it is
important to investigate the inﬂuence of MBL  deﬁciency on
development of SLE in distinct ethnic groups.
Here we report on a study of a large cohort of Brazilian lupus
patients and healthy controls aimed to determine whether low
serum MBL level is a risk factor for SLE in this population.
Materials  and  methods
Study  subjects
286 patients meeting the 1997 updated American College
of Rheumatology (ACR) criteria for SLE12 were sequentially
selected from the Autoimmune Rheumatic Diseases Out-
Patient Clinic at Federal University of Sao Paulo (UNIFESP)
during an eighteen-month period. Three hundred and one
healthy blood donors were recruited after showing no evi-medical interview. Patients and controls were at least 18
years old; each signed the Informed Consent Form, previ-
ously approved by UNIFESP Ethics Committee (CEP n. 0330/09).
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Table 1 – Distribution of subjects with systemic lupus erythematosus according to demographic variables, presence of
co-morbidity, clinical characteristics and medications taken.
n (%) n (%)
Gender (F:M)a 271:15 Current immunosuppressantd 196 (68.5)
Age (years)b 39.29 ± 12.23 • Antimalarialse 198 (69.2)
Disease duration (years) 10.58 ± 7.91 • Corticosteroids 153 (53.4)
SLICC-DI (median/25%–75%) 1/0–2 ≥20 mg (prednisone) 67 (23.4)
SLEDAI (median/25%–75%) 0/0–2 <20 mg (prednisone) 86 (30.1)
Autoimmune rheumatic diseases 20 (6.9) • Azathioprine 65 (22.7)
• APS 14 (4.9) • Methotrexate 48 (16.8)
• Sjögren’s syndrome 6 (2.1) • Cyclophosphamide 23 (8)
Other non-rheumatic autoimmune diseases 14 (4.8) •  Mycophenolate 25 (8.7)
• Hashimoto’s thyroiditis 14 (4.8) •  Leﬂunomide 14 (4.9)
Miscellaneousc 134 (43.8) • Cyclosporine 7 (2.4)
• Tacrolimus 4 (1.4)
• Dapsone 3 (1.0)
• Thalidomide 2 (0.7)
Previous immunosuppressant 186 (65)
APS, antiphospholipid syndrome; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC-DI, Systemic Lupus International
Collaborating Clinics-Damage Index.
a Healthy controls: 286:15 (p = 0.856).
b Healthy controls: 35.1 ± 11.10 (p = 0.070).
c Miscellaneous: non autoimmune diseases, such as arterial hypertension, dyslipidemia, osteoarthritis, etc. Healthy controls: 43 (14.2%;
p < 0.001).
d The sum of subjects using each drug results in a number greater than the total number of patients because some subjects used two or moremedications.
e Antimalarial was not considered immunosuppressant.
Exclusion criteria were: (a) any kind of infection within 30
days before data collection; (b) use of immunobiological med-
ication (inﬂiximab, adalimumab, etanercept, rituximab or
abatacept) within the last 6 months; (c) coexistence of malig-
nant diseases; and (d) HIV infection. Patients underwent a
detailed clinical evaluation, with emphasis on SLE clinical
manifestations, recurrent infections, current and previous
medications, age at SLE onset, evidence of other autoim-
mune diseases, family history, and determination of Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI)13 and
Systemic Lupus International Collaborating Clinics-Damage
Index (SLICC-DI).14 Patients with inactive autoimmune dis-
ease and altered MBL  tests had a second blood sample drawn
after 60 days for re-testing. Patients with any evidence of active
autoimmune disease (SLEDAI ≥ 1) and MBL  deﬁciency were fol-
lowed up to the end of the ﬂare and only then were submitted
to a second blood draw and retesting. Patients were classi-
ﬁed as deﬁcient exclusively after the conﬁrmation of initial
results. In all the cases who were submitted to retest, lab-
oratorial data analyzed were restricted to the second blood
drawn. In regards to the clinical manifestations and disease
activity, clinical data used were restricted to the last activ-
ity period. Lupus nephritis subtypes were deﬁned according
to previous biopsies, when available. Patients with abnormal
results who  continued to exhibit active disease throughout the
study period were excluded.
Evaluation  of  serum  Complement  and  MBL  levelsThe analysis of the Complement components included deter-
mination of total Hemolytic Complement (CH50), C2, C3,
and C4. CH50 and C2 were determined by immunohemolyticassays, as previously reported.15 C3 was determined by
immunoturbidimetry (Olympus®, San Mateo, USA) and C4 by
immunonephelometry (Beckman Coulter®, Brea, USA). Serum
MBL was determined by ELISA (Bioporto Diagnostics®, Gen-
tofte, Denmark) and MBL deﬁciency was deﬁned as serum
levels lower than 1000 g/L and graded according to sever-
ity into mild (<1000 and ≥500 g/L), moderate (<500 and
≥100 g/L) and severe (<100 g/L), as validated by previous
studies.16–20
Statistical  analysis
Continuous variables with normal distribution were ana-
lyzed with Student’s t test and those with non-parametric
distribution were analyzed with the Mann–Whitney test.
Qualitative parameters were analyzed by the Chi-square
test and the Fisher’s exact test when appropriate. Mul-
tiparametric analyses were calculated with the ANOVA
one-way test and post-ANOVA tests (Bonferroni) when
appropriate. Correlation analysis was performed by the Pear-
son’s correlation method. Statistical inference level was set
at 0.05.
Results
Study  population  characteristics
Among the 286 SLE patients there were 271 women and 15
men, with age varying from 18 to 75 years old (39.29 ± 12.23).
Among the 301 normal controls, there were 286 women  and
15 men, with age varying from 18 to 61 years old (35.1 ± 11.1).
Patients and controls did not differ with regard to age and
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Fig. 1 – Systemic lupus erythematosus (SLE) is associated with mild and moderate MBL  deﬁciency. A, distribution of SLE
patients and controls according to severity of MBL  deﬁciency; B, MBL  serum levels in SLE patients and controls. Deﬁnition of
MBL deﬁciency (present in 146 controls and 175 SLE patients), serum MBL  <1000 g/L; mild, serum MBL  <1000 and
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ender distribution, and all of them were descendant from
 blend of different ethnicities, presenting, therefore, a mixed
ackground. Patients presented SLEDAI varying from 0 to 14
1.62 ± 2.81, median: 0) and SLICC-DI varying from 0 to 5
0.95 ± 1.12, median: 1). Duration of disease varied from 1 to
3 years (10.58 ± 7.91). Table 1 depicts the distribution of SLE
atients according to the presence of distinct clinical mani-
estations and medications used.
ild  and  moderate  MBL  deﬁciency  is  more  frequent  in  SLE
atients
LE patients (n = 175; 61.18%) presented higher frequency of
BL  deﬁciency compared to controls (n = 146; 48.50%; p < 0.01),
specially due to mild and moderate MBL  deﬁciency (Fig. 1A).
owever, the overall distribution of MBL  serum levels was sim-
lar in SLE patients and healthy controls (Fig. 1B). There was no
orrelation between MBL  deﬁciency and serum Complement
omponent levels, regardless of the severity of MBL deﬁciency
Table 2).
linical  features  of  SLE  patients  with  MBL  deﬁciencys the laboratory data referred to patients without rele-
ant disease activity (clinical quiescence), all the clinical
ata refer to previous manifestations. Patients with MBL
Table 2 – Lack of correlation between serum MBL  levels and Com
erythematosus.
MBL
deﬁciency
CH50  C2 
Pearson p Pearson 
Overall 0.041 0.491 0.118 0
Mild 0.064 0.657 −0.026 0
Moderate 0.113 0.284 0.204 0
Severe −0.044 0.807 −0.037 0
MBL deﬁciency, serum levels lower than 1000 g/L; mild, serum MBL level <
severe, serum MBL level <100 g/L.rum MBL  <100 g/L.
deﬁciency presented higher frequency of previous lupus
nephritis (class II, III, IV or V) compared to those without
MBL  deﬁciency, regardless of the severity of MBL  deﬁciency
(Table 3). No other clinical manifestation, including recur-
rent infections, presented different frequency in SLE patients
with and without MBL deﬁciency (Table 3). There was also
no difference between these two subgroups regarding the
presence of other autoimmune rheumatic diseases, non-
rheumatic autoimmune diseases or other non-autoimmune
diseases (miscellaneous), disease severity, cumulative dam-
age, current age, disease duration, age at SLE onset (Table 3),
and previous or current use of immunosuppressant (Table 4).
Finally, no correlation between MBL serum levels and disease
severity or cumulative damage was observed (Table 5).
Discussion
In the present study, we determined the frequency and pos-
sible clinical implications of MBL deﬁciency in a large cohort
of Brazilian SLE patients. We observed an increased frequency
of mild and moderate MBL  deﬁciency in SLE patients com-
pared to healthy controls. Interestingly, our results showed
higher frequency of lupus nephritis in association with MBL
deﬁciency regardless of the severity of MBL  deﬁciency. One
concern was the possibility that the low serum MBL  observed
plement levels in subjects with systemic lupus
C3 C4
p Pearson p Pearson p
.067 0.019 0.751 −0.125 0.233
.857 0.154 0.285 0.215 0.363
.051 0.024 0.819 0.022 0.907
.839 −0.289 0.102 −0.011 0.979
1000 and ≥500 g/L; moderate, serum MBL level <500 and ≥100 g/L;
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Table 3 – Distribution of subjects with systemic lupus erythematosus according to the severity of MBL  deﬁciency and the
previous clinical manifestation and demographic characteristics of the disease.
Clinical
features
No  MBL
deﬁciency
n = 111
MBL  deﬁciency
Overall
n = 175
Mild
n = 50
Moderate
n  = 92
Severe
n = 33
Gender M:F 3:108 12:163 2:48 7:85 3:30
Cutaneous %a 94.6 89.7 92.0 88.0 90.9
Oral ulcers % 18.9 22.9 32.0 21.7 12.11
Arthritis % 83.8 88.6 88.0 88.0 90.9
Nephritis % 47.7 60.6b 74.0c 61.1b 66.7b
II % 1.3 1.8 2.1 1.5 1.6
III % 8.6 8.5 8.1 9.6 7.9
IV % 13.2 12.2 13.6 13.2 13.9
V % 5.7 6.2 6.1 4.8 5.0
No biopsy available % 18.9 19.4 18.5 18.9 19.8
Hematologic disease % 68.5 65.1 60.0 66.3 69.7
Serositis % 21.6 32.0 24.0 33.7 39.4
Neuropsychiatric % 18.9 22.9 28.0 20.7 21.2
Recurrent infection % 9.0 8.6 2.0 10.9 12.11
Other SARD % 8.1 6.9 4.0 7.6 9.1
NRAID % 1.8 6.9 12.0 3.3 9.1
Miscellaneous % 48.6 45.7 56.0 40.2 45.5
Age Mean ± SD 38.7 ± 11.8 39.2 ± 12.9 38.7 ± 12.1 37.9 ± 13.0 43.3 ± 13.0
Disease duration 9.7 ± 7.1 10.8 ± 8.0 10.3 ± 7.4 11.0 ± 8.5 11.0 ± 7.6
Age at SLE onset 28.9 ± 10.4 28.3 ± 11.0 28.4 ± 10.9 26.8 ± 10.7 32.2 ± 11.14
SLEDAI Median (min–max) 0 (0–11) 0 (0–12) 0 (0–6) 0 (0–8) 1 (0–12)
SLICC-DI 1 (0–4) 1 (0–5) 1 (0–4) 1 (0–5) 1 (0–3)
MBL deﬁciency, serum levels lower than 1000 g/L; mild, serum MBL level <1000 and ≥500 g/L; moderate, serum MBL level <500 and ≥100 g/L;
severe, serum MBL level <100 g/L; SARD, systemic autoimmune rheumatic diseases; NRAID, non-rheumatic autoimmune diseases; miscella-
neous, any non-rheumatic and non-autoimmune disease; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC-DI, Systemic
Lupus International Collaborating Clinics-Damage Index.
a Percentages refer to the frequency of any given clinical manifestation.
b p < 0.05.
c p < 0.01.
Table 4 – Distribution of subjects with systemic lupus erythematosus according to the severity of MBL  deﬁciency and use
of immunosuppressant therapy.
No MBL deﬁciency MBL deﬁciency
n = 111 Overall
n = 175
Mild
n  = 50
Moderate
n  = 92
Severe
n  = 33
Current immunosupressanta %b 64.0 71.4 68.0 71.7 75.8
Previous immunosupressanta % 63.6 66.7 74.0 63.7 63.6
Corticosteroids
Totala % 52.3 54.9 66.0 45.7 57.6
Low dosesa % 32.4 28.6 32.0 26.1 36.4
High dosesa % 19.80 25.7 34.0 19.6 21.2
Anti-malarialsa % 73.0 66.9 70.0 59.8 81.8
Azathioprinea % 21.6 23.40 24.0 25.0 18.2
Mycophenolatea % 9.9 8.0 8.0 6.5 12.1
Methotrexatea % 13.5 18.9 16.0 17.4 27.3
Cyclophosphamidea % 7.2 8.6 6.0 10.9 6.1
Leﬂunomidea % 5.4 4.6 4.0 3.3 9.1
Dapsonea % 1.8 0.6 2.0 0 0
Thalidomidea % 0.9 0.6 0 1.1 0
Tacrolimusa % 0.9 1.7 2.0 2.2 0
Cyclosporinea % 1.8 2.9 6.0 1.1 3.0
MBL deﬁciency, serum levels lower than 1000 g/L; mild, serum MBL level <1000 and ≥500 g/L; moderate, serum MBL level <500 and ≥100 g/L;
severe, serum MBL level <100 g/L.
a No statistically signiﬁcant association.
b Percentages refer to the frequency of any given clinical manifestation.
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Table 5 – Lack of correlation between MBL  serum levels and disease activity or cumulative damage in subjects with
systemic lupus erythematosus.
MBL deﬁciency SLEDAI  SLICC-DI
Correlationa p Correlation p
Overall −0.068 0.256 −0.05 0.945
Mild 0.037 0.800 −0.090 0.631
Moderate 0.107 0.310 0.163 0.160
Severe 0.036 0.840 −0.322 0.154
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC-DI, Systemic Lupus International Collaborating Clinics-Damage Index;
MBL deﬁciency, serum levels lower than 1000 g/L; mild, serum MBL level <1000 and ≥500 g/L; moderate, serum MBL level <500 and ≥100 g/L;
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a Calculated according to Pearson’s test.
n some patients could be secondary to disease activity or
mmunosuppressant therapy. However, this seems not to be
he case, since follow up assessment after SLE disease activ-
ty has conﬁrmed the initial MBL  deﬁcient classiﬁcation in all
ases. In addition, there was no difference in the frequency
f MBL  deﬁciency according to SLE activity and severity.
o association was observed between MBL  deﬁciency and
mmunosuppressant use or recurrent infections.
Traditionally, immunodeﬁcient states are associated with
ncreased susceptibility to infection. MBL  deﬁciency has been
escribed as a risk factor for infectious diseases.21–23 How-
ver, microbicide activity is not the sole function of MBL:
t can also bind apoptotic cells and initiate their uptake by
acrophages.24,25 Therefore, it is possible that MBL deﬁciency
ould lead to decreased clearance of autoantigens, which
ould in turn contribute to the development of autoimmunity.
e propose that mild or moderate immunologic deﬁcits such
s MBL  deﬁciency may impact the inﬂammatory process and
ventual development of autoimmune diseases even without
ncreasing susceptibility to infections.
The association between MBL  deﬁciency and SLE is still
ontroversial and disparate results have been obtained in
ifferent ethnic groups, including American11 and African10
opulations. In this regard, the present study makes an impor-
ant contribution, since it conﬁrms the association in a sample
f the Brazilian population, which represents a unique blend
f European, African and native American Indian descen-
ants. Another source of controversy is the lack of a clear
eﬁnition of MBL  deﬁciency. In this study we deﬁned three
egrees of MBL  deﬁciency severity based on serum MBL  lev-
ls, as has been done in several previous studies.16–20 There
s some concern that anti-MBL autoantibodies in the serum
f SLE patients might lead to secondary MBL deﬁciency with-
ut underlying MBL  genetic abnormality. This could partially
xplain conﬂicting ﬁndings on the association between MBL
eﬁciency and SLE.8,11,26 As an alternative, some studies have
sed MBL  polymorphisms in the promoter region or the coding
egion as criteria for deﬁnition of MBL  deﬁciency.3,4,7–9 How-
ver, there is no perfect correlation between the presence of
BL polymorphisms and protein expression, and therefore
he real value of this approach is still unclear.
In this study, we  observed a higher frequency of lupusephritis in subjects with SLE and MBL  deﬁciency than in sub-
ects with SLE and normal MBL  levels. Several previous studies
ave suggested links between MBL  levels and lupus nephritis.Anti-MBL autoantibodies can bind to MBL  deposited in tis-
sues and contribute to local injury, as demonstrated in kidneys
of SLE patients.27 It has been also reported that the nucleic
acid-binding capacity of MBL plays an important role in the
clearance of DNA, an important autoantigen for lupus nephri-
tis development.28 Piao et al.29 in a North American population
and Asgharzadeh et al.30 in an Azerbaijan population in Iran
demonstrated that homozygosis for MBL  variants is a disease-
modifying factor, particularly for renal involvement. However,
the relationship between MBL deﬁciency and lupus nephritis
may be affected by ethnic background, since Bertoli et al.31
showed in a large multiethnic lupus cohort composed by
Hispanics, African American and Caucasians that carriers of
variant alleles for MBL gene had lower frequency of lupus
nephritis and serositis, but higher frequency of leukopenia.
Besides the decrease in antigen clearance, homozygosis for
MBL  variant alleles is also associated with an increase in risk
of infections, mainly in children.32,33 Consequently, patients
with MBL deﬁciency are at higher risk of being exposed more
frequently and for longer periods of time to pathogens that
may play a role in SLE pathogenesis. It should be pointed
out that a previous report found no association between MBL
deﬁciency and severe infections in SLE patients,34 and this
was conﬁrmed in the present study. Furthermore, it has been
reported that MBL-deﬁcient adults do not present increased
frequency of infectious diseases, leading to the assumption
that a second immune defect might be needed to trigger sus-
ceptibility to infection.35
The exact mechanism underlying the effect of MBL deﬁ-
ciency on the pathogenesis and clinical outcome of SLE is not
clear. Takahashi et al.36 showed positive, although weak, cor-
relation between serum CH50 activity and serum MBL levels,
suggesting that MBL could also be used as a marker for dis-
ease activity in SLE patients. In the present study, we  could
not demonstrate any correlation between serum MBL  levels
and Complement levels, SLE disease activity or cumulative
damage. Regardless of the pathophysiology involved, MBL
deﬁciency per se is probably not enough to induce autoim-
munity. Additional, yet unknown factors may act in concert
with MBL deﬁciency to trigger development of autoimmunity.
Further studies are needed to address this question.
In summary, analysis of serum MBL levels in a large cohort
of adult Brazilian SLE patients and healthy controls showed
that mild and moderate MBL deﬁciency is associated with
SLE in this study population. Moreover, we  observed that SLE
 o l . 2
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2226  r e v b r a s r e u m a t
patients with MBL  deﬁciency had higher prevalence of lupus
nephritis, regardless of the severity of MBL  deﬁciency, than SLE
patients with normal MBL  levels. These results obtained in the
ethnically unique and complex Brazilian population frame-
work add another piece to the puzzle of the association of
MBL deﬁciency and SLE.
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